Hansa Biopharma Ab · OMXSTO:HNSA
Hansa Biopharma Ab — Q1 2025 Earnings Presentation
19 slides from Hansa Biopharma Ab's earnings presentation, Apr 24, 2025
Slide 1: Q1 2025 Results Conference Call
Q1 2025 Results Conference Call April 24, 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occ
Slide 3: Q1 2025 Results Conference Call Agenda
Q1 2025 Results Conference Call Agenda 24 April 2025 Chairman Remarks Peter Nicklin Chairman of the Board Operational Update Peter Nicklin Chairman of the Board Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Peter Nicklin Chai
Slide 4: Steady growth compared to PY and continued pipeline progress
Steady growth compared to PY and continued pipeline progress Q1 ‘24 Q1 ‘25 ✓ 39% increase in quarterly sales as compared to previous year Sales 47.4 65.7 Revenue MSEK MSEK ✓ 18% increase in total revenue as compared to previous year Total 56.0 66.3 ✓ Post Authorization Efficacy and Safety Revenue MS
Slide 5: Ongoing pipeline progress in Q1 2025
Ongoing pipeline progress in Q1 2025 ConfIdeS Ph 3 PAES Ph 3 GOOD-IDES-02 Ph 3 15-HMedIdeS-09 Ph 2 (kidney transplant) (kidney transplant) (anti-GBM) (GBS) Enrolment complete Enrolment complete Enrolment complete Ph 2 and indirect treatment data read out 2H 2025 data read out in 2026 data read out i
Slide 6: PAES study completed enrolment; anticipate increased commercial utilization in key EU markets
PAES study completed enrolment; anticipate increased commercial utilization in key EU markets • Open label Phase 3 study ABOUT • 50 highly sensitized patients with positive crossmatch against an available deceased donor across PAES multiple countries and centers in Europe • Obligation to the EMA to
Slide 7: Commercialization of IDEFIRIX in the EU continues to gain momentum
Commercialization of IDEFIRIX in the EU continues to gain momentum Clinical Patient Selection Market Readiness & Treatment Access 117 clinics are IDEFIRIX ready 200+ local scientific events Reimbursement in 18 markets incl. to treat and global engagements largest EU markets *3 additional markets in
Slide 8: Q1 2025 Results Conference Call Agenda
Q1 2025 Results Conference Call Agenda 24 April 2025 Chairman Remarks Peter Nicklin Chairman of the Board Operational Update Peter Nicklin Chairman of the Board Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Peter Nicklin Chai
Slide 9: Broad clinical pipeline
Broad clinical pipeline Marketing Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner Sta tus Next anticipate d milestone authoriza tion Imlifidase EU: Kid ney transplan tation in highly Commercialization ongoing EU: Additional agreements around sensitized patients 1 ,2 Post approval Clinical reimb
Slide 10: Advancing the science in Autoimmune, Gene Therapy, and Transplantation
Advancing the science in Autoimmune, Gene Therapy, and Transplantation TRANSPLANT AUTOIMMUNE TRANSPLANTATION Delivering the Pipeline 15-HMedIdeS-09 Ph 2 (GBS) US ConfIdeS Ph 3 (kidney) Indirect Treatment Comparison and Enrolment COMPLETE 8 Ongoing clinical trials in autoimmune, Full data read out CO
Slide 11: Long-term follow-up study and extended pooled analysis showed durable graft and patient survival
Long-term follow-up study and extended pooled analysis showed durable graft and patient survival Study Overview 17-HMedIdeS-14 is a prospective, observational, long-term follow-up study of patients treated with imlifidase prior to kidney transplantation to measure long-term graft survival in patient
Slide 12: Q1 2025 Results Conference Call Agenda
Q1 2025 Results Conference Call Agenda 24 April 2025 Chairman Remarks Peter Nicklin Chairman of the Board Operational Update Peter Nicklin Chairman of the Board Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Peter Nicklin Chai
Slide 13: Strong Q1 2025 IDEFIRIX sales performance
Strong Q1 2025 IDEFIRIX sales performance Revenue (Q/Q) Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 78.4 29.7 * 66.3 Product sales 56.0 54.2 MSEK 65.7 (net of pr ovision) 47.4 19.9 * 39.8 32.3 27.2 25.6 Contr act revenue** 8.6 7.1 8.9 6.7 0.6 *Provision Revenue (FY/FY) Product Sales, Trailing 12 months (TTM) 2022
Slide 14: Continued investments in R&D and commercialization
Continued investments in R&D and commercialization SG&A expenses (Q/Q) R&D expenses (Q/Q) Operating loss (Q/Q) Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 -64 -76 -76 -80 -92 -93 MSEK MSEK -101 MSEK -103 -91 -117 -89 -88 -159 -174 -187 SG&A expenses (FY/
Slide 15: Summary of cash and headcount
Summary of cash and headcount Operating cash flow (Q/Q) Cash & Cash Equivalents (Q/Q) Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 705 MSEK MSEK 541 554 405 -149 -148 -152 250 -189 -189 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Operating cash flow (FY/FY) Number of employees (Q/Q) 2022 2023 2024 166 166 Employees 146 MSEK 135
Slide 16: Q1 2025 Results Conference Call Agenda
Q1 2025 Results Conference Call Agenda 24 April 2025 Chairman Remarks Peter Nicklin Chairman of the Board Operational Update Peter Nicklin Chairman of the Board Pipeline Update Hitto Kaufmann Chief R&D Officer Financial Results Evan Ballantyne Chief Financial Officer Close and Q&A Peter Nicklin Chai
Slide 17: Hansa Biopharma Leadership
HANSA BIOPHARMA LEADERSHIP Peter Nicklin Renée Aguiar-Lucander Hitto Kaufmann Evan Ballantyne Chairman of the CEO Chief R&D Officer CFO Board © 2025 H ansa Biopharma AB
Slide 18: Hansa Biopharma contacts and key events
Hansa Biopharma contacts and key events Contacts Calendar and events Evan Ballantyne 2025 Chief Financial Officer Email: ir@hansabiopharma.com To be Determined Annual General Meeting 2025 16 JUN Autoimmune Science Deep Dive – GBS 17 JULY Half Year Report (January – June) Stephanie Kenney 23 OCT Inte
Slide 19: HAN Sar
MZ HAN Sar BIOPHARMA